325 related articles for article (PubMed ID: 24602465)
21. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
23. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
24. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
Tylicki L; Lizakowski S; Rutkowski B
J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
[TBL] [Abstract][Full Text] [Related]
25. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
Ram CV
Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
[TBL] [Abstract][Full Text] [Related]
26. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
Wong J
Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
[TBL] [Abstract][Full Text] [Related]
27. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
28. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
[TBL] [Abstract][Full Text] [Related]
29. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
Gaddam KK; Oparil S
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389
[TBL] [Abstract][Full Text] [Related]
30. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
31. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
32. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
Kalaitzidis R; Bakris G
Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
[TBL] [Abstract][Full Text] [Related]
33. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
[TBL] [Abstract][Full Text] [Related]
35. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Chen SS; Seliger SL; Fried LF
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
[TBL] [Abstract][Full Text] [Related]
36. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
37. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
Chrysant SG; Chrysant GS
Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
[TBL] [Abstract][Full Text] [Related]
38. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI; Agarwal R
Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
[TBL] [Abstract][Full Text] [Related]
39. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
40. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
